Table 3.
Hazard ratios (HR) with 95% confidence interval (95% CI) of cancer case fatality by cancer site, according to predefined cancer-specific categories of prediagnostic (I) and diagnostic (II) 25-OHD serum levels. The two serum samples were collected in average 14.4 years apart
| Cancer site | ||||
|---|---|---|---|---|
| Breast HR (95% CI)a | Colon HR (95% CI)a | Lung HR (95% CI)a | Lymphoma HR (95% CI)a | |
| nb | 202/68 | 37/22 | 193/168 | 124/55 |
| I. Prediagnostic 25-OHDc | ||||
| 1 | 1.00 | 1.00 | 1.00 | 1.00 |
| 2 | 0.66 (0.36–1.21) | 0.24 (0.04–1.49) | 1.08 (0.63–1.86) | 0.40 (0.15–1.09) |
| 3 | 0.66 (0.35–1.25) | 0.28 (0.06–1.31) | 0.74 (0.45–1.23) | 1.05 (0.44–2.50) |
| 4 | 0.39 (0.14–1.06) | 0.61 (0.13–2.91) | 0.55 (0.31–0.96) | 0.29 (0.10–0.82) |
| p for trend | 0.055 | 0.925 | 0.004 | 0.184 |
| II. Diagnostic 25-OHDc | ||||
| 1 | 1.00 | 1.00 | 1.00 | 1.00 |
| 2 | 0.40 (0.19–0.81) | 1.15 (0.30–4.43) | 0.52 (0.34–0.81) | 0.91 (0.45–1.86) |
| 3 | 0.44 (0.22–0.87) | 0.53 (0.14–1.97) | 0.48 (0.31–0.75) | 0.38 (0.17–0.88) |
| 4 | 0.32 (0.15–0.67) | 0.18 (0.03–0.98) | 0.30 (0.19–0.47) | 0.36 (0.16–0.81) |
| p for trend | 0.008 | 0.033 | <0.001 | 0.003 |
Notes: aAdjusted for sex, age at diagnosis, season of serum sampling, and serum storage time; bNumber of case/deaths due to cancer; cCancer-specific category limits of 25-OHD (nmol/L): breast ≤50, 51–67, 68–86, >86; colon ≤44, 45–56, 57–77,>77; lung ≤41, 42–56, 57–76,>76; lymphoma ≤44, 45–60, 61–77,>77.